证券代码：688755 证券简称：汉邦科技 公告编号：2025-019 江苏汉邦科技股份有限公司 关于变更公司经营范围暨修订 <公司章程> 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏汉邦科技股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日召开 第一届董事会第二十二次会议，审议通过《关于变更公司经营范围暨修订 <公司> 章程>的议案》，尚需提交公司股东会审议。具体情况如下： 一、变更经营范围的情况 根据公司业务发展需要，依照企业经营范围登记管理规范性要求，拟对公司 经营范围进行变更。具体变更情况如下: 本次变更前经营范围： 液相色谱柱、动态轴向压缩柱、静态轴向压缩柱、液相色谱仪器、超临界流 体色谱仪器、蛋白纯化色谱仪器、制备液相色谱系统设备、模拟移动床色谱系统 设备、蛋白纯化系统设备、超临界色谱系统设备、渗透汽化分离设备、溶剂回收 及纯化设备、生物大分子层析柱、生物大分子层析系统设备和超滤系统设备的研 发、制造、销售；仪器配件加工、销售；分析试剂、日用化学品、玻璃仪器、机 电设备销售及技术 ...

江苏汉邦科技股份有限公司 章 程 江苏汉邦科技股份有限公司 章程 目 录 江苏汉邦科技股份有限公司 章 程 第一章 总 则 第一条 为维护江苏汉邦科技股份有限公司（以下简称"公司"）、股东、职 工和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司法》 （以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、 《上市公司章程指引》、《上海证券交易所科创板股票上市规则》和其他有关规 定，制订本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司。 公司系由江苏汉邦科技股份有限公司全体股东作为发起人，并于 2022 年 2 月 25 日整体变更设立的股份有限公司，在淮安市行政审批局注册登记，取得营 业执照，统一社会信用代码为 913208917038195227。 第三条 公司经上海证券交易所审核并经中国证券监督管理委员会于 2025 年 3 月 4 日注册，首次向社会公众发行人民币普通股 2,200 万股，于 2025 年 5 月 16 日在上海证券交易所科创板上市。 第四条 公司注册名称：江苏汉邦科技股份有限公司。 英文名称：Jiangsu Hanbon Scie ...

Core Viewpoint - Jiangsu Hanbang Technology Co., Ltd. is convening its first extraordinary general meeting of shareholders in 2025 to discuss significant changes including alterations to the company's registered capital, type, business scope, and governance structure [1][5]. Group 1: Meeting Procedures - Shareholders and their proxies must register 30 minutes before the meeting and present necessary identification to attend [1][2]. - After the meeting starts, attendance registration will cease, and latecomers will not be allowed to vote [2]. - The meeting will follow a predetermined agenda for reviewing and voting on proposals [2][5]. Group 2: Proposals Overview - The primary proposal includes changes to the company's registered capital, type, and business scope, as well as the cancellation of the supervisory board and amendments to the company’s articles of association [5][10]. - The company plans to increase its registered capital from RMB 66 million to RMB 88 million following its initial public offering of 22 million shares on May 16, 2025 [7]. - The business scope will be expanded to include new areas such as mechanical equipment research and development, software development, and various manufacturing activities [7][8]. Group 3: Governance Changes - The company will abolish the supervisory board, transferring its powers to the audit committee of the board of directors [8][9]. - Amendments to the articles of association will be proposed, with the aim of enhancing corporate governance and operational efficiency [10]. - The revised articles and related documents will be disclosed on the Shanghai Stock Exchange website [9][10].

Core Points - Jiangsu Hanbon Technology Co., Ltd. has announced changes to its registered capital, company type, business scope, and governance structure, including the cancellation of the supervisory board and amendments to the Articles of Association [1][2][5] Capital and Company Type Changes - The registered capital of the company will increase from RMB 66 million to RMB 88 million following the initial public offering of 22 million shares [2][8] - The company type will change from "non-listed limited company" to "listed limited company" as it is now listed on the Sci-Tech Innovation Board [2][8] Business Scope Changes - The business scope will be updated to include the research, manufacturing, and sales of various chromatography columns and instruments, as well as special equipment and technology services [3][4][9] - The new business scope will also encompass the manufacturing and sales of mechanical equipment, biochemistry products, and software development [4][9] Governance Structure Changes - The supervisory board will be abolished, and its functions will be transferred to the audit committee of the board of directors [5][6] - The Articles of Association will be revised to reflect these changes, with specific amendments highlighted in the accompanying documents [5][6] New and Revised Governance Systems - The company will introduce and amend several governance systems to enhance operational standards and protect shareholder rights [6][7] - The revised Articles of Association and governance systems will be disclosed on the Shanghai Stock Exchange website [6][7]

General Provisions - Jiangsu Hanbon Science & Technology Co., Ltd. was established as a joint-stock company in accordance with the Company Law and other relevant regulations, with its registration completed on February 25, 2022 [1][2] - The company received approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission for its initial public offering of 22 million shares, which took place on May 16, 2025 [1][2] - The registered capital of the company is RMB 88 million [2] Business Objectives and Scope - The company's business objective is to enhance management efficiency and maximize economic benefits to provide satisfactory returns to all shareholders [4] - The business scope includes research, manufacturing, and sales of various chromatography equipment and systems, as well as related technical services and consulting [5][6] Shares - The company issues shares in the form of stocks, with a par value of RMB 1 per share [6][7] - The total number of shares issued by the company is 88 million, all of which are ordinary shares [7] Shareholder Rights and Responsibilities - Shareholders have rights to dividends and other benefits proportional to their shareholdings, and they can participate in shareholder meetings and exercise voting rights [12][13] - Shareholders are obligated to comply with laws and regulations, pay for their subscribed shares, and not misuse their rights to harm the company or other shareholders [17][40] Shareholder Meetings - The company holds annual shareholder meetings within six months after the end of the previous fiscal year, and special meetings can be called under certain conditions [50][51] - Shareholder proposals must be submitted in writing and can be made by the board, audit committee, or shareholders holding more than 1% of shares [60][61] Governance and Management - The board of directors is responsible for the overall management of the company, and the chairman serves as the legal representative [2][3] - The company has established an audit committee to oversee compliance and financial reporting [15][16]

Core Viewpoint - Nanwei Technology (688690) is experiencing growth driven by the booming GLP-1 peptide drug market, leading to increased investment in new drug research and production capacity by domestic and international pharmaceutical companies [2][3]. Group 1: Business Performance - The company's main revenue for Q1 2025 was 189 million yuan, a year-on-year increase of 22.39%, with a net profit attributable to shareholders of 29.22 million yuan, up 72.98% year-on-year [7]. - The gross profit margin for the chromatography filler business is high, accounting for approximately 60% of the company's revenue, which has improved overall profitability [4]. Group 2: Market Strategy - The company is focusing on the antibody new drug projects as a key area for replacing imported products, enhancing competitiveness through continuous R&D investment and product innovation [3]. - To address domestic competition, the company is building a comprehensive chromatography technology platform, providing integrated solutions to avoid price wars in single product categories [6]. Group 3: Mergers and Acquisitions - The acquisition of two instrument companies enhances the company's product line from chromatography fillers to protein purification equipment, improving business and product layout and achieving synergy in customer expansion and market sales [5]. Group 4: Future Outlook - The company is accelerating its overseas market layout and enhancing its overseas sales capabilities to increase application opportunities for its filler products among international clients [3][6].

股票简称：汉邦科技 股票代码：688755 江苏汉邦科技股份有限公司 Jiangsu Hanbon Science and Technology Co., Ltd. （淮安经济技术开发区新竹路 10 号；淮安经济技术开发区集贤路 1-9 号） 首次公开发行股票科创板上市公告书 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 二〇二五年五月十五日 江苏汉邦科技股份有限公司 上市公告书 特别提示 江苏汉邦科技股份有限公司（以下简称"汉邦科技"、"本公司"、"发 行人"、"公司"）股票将于 2025 年 5 月 16 日在上海证券交易所科创板上市。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在 新股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 1 江苏汉邦科技股份有限公司 上市公告书 第一节 重要声明与提示 一、重要声明与提示 本公司及全体董事、监事、高级管理人员保证上市公告书所披露信息的真 实、准确、完整，承诺上市公告书不存在虚假记载、误导性陈述或重大遗漏， 并依法承担法律责任。 上海证券交易所、有关政府机关对本公司股票上市及有关事项的意见，均 不表明 ...